Why top US GxP companies are rethinking environmental compliance
3 major market forces are reshaping US pharma compliance.
As a result, leading US pharma companies are changing how they manage environmental compliance. Here is what it means for your cold chain, your compliance model, and your operation.
The 3 forces reshaping US pharma compliance
Three structural shifts are changing what the US pharma cold chain looks like – and what it demands from the compliance programs built to manage it.
- Biologics and new drug pipelines
- US onshoring
- Pharma 4.0 and technology pressure
All three forces are expanding and complicating the pharmaceutical cold chain.
The traditional compliance model was not designed for a cold chain this long, complex, or fast.
In the webinar, we will walk through the market forces changing pharma in the US – what they are and why they are happening.
Sign up for the webinar
When: April 29th, 2026
- 9.30 A.M. CDT
- 10.30 A.M. EDT
- 3.30 P.M. BST
- 4.30 P.M. CEST
What you will learn
- The 3 forces that are reshaping US pharma compliance
- How the dynamics are stretching the pharma cold chain (and breaking the traditional compliance models built to manage it)
- What it means for your GxP operation - whether based in the US or working with US partners
- What the companies navigating this well are doing differently.
About the speakers
Adam Hartmann-Kruckow is a co-founder and CCO of Eupry, with over a decade of experience building monitoring systems for GxP – from early UNICEF vaccine cold chain projects to supporting global pharma. Adam leads Eupry's North American division, working side by side with US GxP teams on a daily basis.
Devin Kelley is Eupry's US GTM lead. His work focuses on connecting validation consultancies, storage builders, and manufacturing organizations to Eupry's digital compliance platform, spending most of his time in conversations US GxP teams are having before they make a monitoring decision.
